Vericel Corp (NASDAQ:VCEL) Expected to Post Earnings of -$0.06 Per Share

Analysts forecast that Vericel Corp (NASDAQ:VCEL) will announce earnings per share of ($0.06) for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Vericel’s earnings, with the highest EPS estimate coming in at ($0.02) and the lowest estimate coming in at ($0.09). Vericel reported earnings per share of $0.07 during the same quarter last year, which would suggest a negative year over year growth rate of 185.7%. The company is scheduled to issue its next quarterly earnings report on Tuesday, November 3rd.

On average, analysts expect that Vericel will report full year earnings of ($0.17) per share for the current year, with EPS estimates ranging from ($0.28) to ($0.12). For the next financial year, analysts expect that the business will report earnings of $0.38 per share, with EPS estimates ranging from $0.24 to $0.71. Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that cover Vericel.

Vericel (NASDAQ:VCEL) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.03. The firm had revenue of $20.00 million for the quarter, compared to analysts’ expectations of $19.31 million. The firm’s quarterly revenue was down 23.7% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.05) earnings per share.

Several research firms have commented on VCEL. BidaskClub raised shares of Vericel from a “hold” rating to a “buy” rating in a research note on Tuesday, September 15th. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price objective on shares of Vericel in a research note on Thursday, August 6th. Oppenheimer reiterated a “buy” rating and set a $32.00 target price on shares of Vericel in a research report on Monday. Truist assumed coverage on Vericel in a research report on Thursday, September 17th. They set a “buy” rating and a $24.00 target price for the company. Finally, Needham & Company LLC assumed coverage on Vericel in a research report on Wednesday, August 5th. They set a “hold” rating for the company. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $23.17.

Several hedge funds have recently modified their holdings of the company. Two Sigma Advisers LP grew its stake in shares of Vericel by 60.6% during the second quarter. Two Sigma Advisers LP now owns 180,000 shares of the biotechnology company’s stock worth $2,488,000 after acquiring an additional 67,900 shares during the last quarter. Schonfeld Strategic Advisors LLC grew its stake in shares of Vericel by 1.9% during the second quarter. Schonfeld Strategic Advisors LLC now owns 41,127 shares of the biotechnology company’s stock worth $569,000 after acquiring an additional 769 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Vericel by 6.9% during the second quarter. Charles Schwab Investment Management Inc. now owns 299,978 shares of the biotechnology company’s stock worth $4,146,000 after acquiring an additional 19,312 shares during the last quarter. Jane Street Group LLC grew its stake in shares of Vericel by 81.5% during the second quarter. Jane Street Group LLC now owns 20,643 shares of the biotechnology company’s stock worth $285,000 after acquiring an additional 9,272 shares during the last quarter. Finally, Kopp Family Office LLC grew its stake in shares of Vericel by 44.6% during the second quarter. Kopp Family Office LLC now owns 1,082,155 shares of the biotechnology company’s stock worth $14,955,000 after acquiring an additional 333,900 shares during the last quarter. Institutional investors and hedge funds own 94.98% of the company’s stock.

NASDAQ VCEL traded up $0.52 on Tuesday, hitting $18.92. 527,158 shares of the stock were exchanged, compared to its average volume of 670,069. The company has a debt-to-equity ratio of 0.19, a quick ratio of 5.92 and a current ratio of 6.39. The stock has a fifty day moving average price of $16.54 and a two-hundred day moving average price of $14.26. The firm has a market capitalization of $856.13 million, a P/E ratio of -1,892.00 and a beta of 2.88. Vericel has a 52-week low of $6.78 and a 52-week high of $19.64.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.

Featured Story: Profit margin is different from the revenue

Get a free copy of the Zacks research report on Vericel (VCEL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.